<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514629</url>
  </required_header>
  <id_info>
    <org_study_id>CMCS240281</org_study_id>
    <nct_id>NCT02514629</nct_id>
  </id_info>
  <brief_title>Testosterone, Metformin, or Both, for Hypogonadism in Obese Males</brief_title>
  <official_title>Randomized, Double-blind, Parallel, Placebo-controlled, Clinical Trial to Assess the Efficacy of Testosterone, Metformin, or Both, for the Treatment of Obesity-induced Male Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of metformin, testosterone, or both, in
      males with obesity-related hypogonadism. This study will evaluate changes in insulin
      resistance, weight loss, body composition, testosterone levels,quality of life and erectile
      dysfunction.

      Obese men will receive diet and physical activity counselling, and be randomised to either
      testosterone, metformin, a combination of both or placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 4, 2013</start_date>
  <completion_date type="Actual">July 12, 2016</completion_date>
  <primary_completion_date type="Actual">July 12, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Insulin Resistance</measure>
    <time_frame>Basal-52 weeks</time_frame>
    <description>Insulin resistance will be measured using Homeostasis Model of Assessment for Insulin Resistance index (HOMA-IR index)
HOMA-IR=FINS*FGLU/22.5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight</measure>
    <time_frame>Basal-52 weeks</time_frame>
    <description>Body weight will be measured on a Tanita Multi-Frequency Body Composition Analyzer MC-180MA (Tanita Corporation, Tokyo, Japan) to assess change in body weight over the 52-week intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Erectile Dysfunction</measure>
    <time_frame>Basal-52 weeks</time_frame>
    <description>Changes in Erectile Dysfunction will be evaluated with the International Index of Erectile Function (IIEF-5) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Aging Male Symptom (AMS) Scale</measure>
    <time_frame>Basal-52 weeks</time_frame>
    <description>Change from baseline on the total score of the AMS rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Androgen Deficiency in the Aging Male (ADAM) Questionnaire</measure>
    <time_frame>Basal-52 weeks</time_frame>
    <description>Change from baseline on the ADAM Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Testosterone Levels (Total and Free)</measure>
    <time_frame>Basal-52 weeks</time_frame>
    <description>The change from baseline to week 52 in free testosterone and total testosterone levels will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Composition (Fat and Lean Mass)</measure>
    <time_frame>Basal-52 weeks</time_frame>
    <description>Body Composition will be measured on a Tanita Multi-Frequency Body Composition Analyzer MC-180MA (Tanita Corporation, Tokyo, Japan) to assess changes in body composition (fat mass, lean mass, total body water) over the 52-week intervention period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biochemical Markers of Bone Turnover</measure>
    <time_frame>Basal-52 weeks</time_frame>
    <description>Change in Bone turnover, measured by serum procollagen type I N-terminal propeptide (PINP) and Beta-CrossLaps (β-CTx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Metabolic Hormones</measure>
    <time_frame>Basal-52 weeks</time_frame>
    <description>Changes in Leptin, adiponectin, betatrophin and kisspeptin levels</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 850 mg tablets twice daily for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 850 mg tablets twice daily + Testosterone Undecanoate 1000 mg/4ml im injection each 12 weeks for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
    <other_name>Dianben</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Undecanoate</intervention_name>
    <arm_group_label>Testosterone</arm_group_label>
    <other_name>Nebido</other_name>
    <other_name>Reandron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin + Testosterone Undecanoate</intervention_name>
    <arm_group_label>Metformin + Testosterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 18 to 50 years.

          -  BMI &gt; or = 30 kg/m2.

          -  Total testosterone levels &lt;2.3 ng/ml (&lt;8 nmol/l) or testosterone levels 2.3-3.49 ng/ml
             (8-12 nmol/l) and free testosterone levels &lt;70 pg/ml.

          -  LH levels &lt;7.7 mIU / ml.

          -  No evidence of any other pituitary hormone disruption in morning blood sample (normal
             concentrations of TSH, FT4, Prolactin, ACTH, cortisol and IGF-1

          -  Being able to provide informed consent before randomization and agree to comply with
             all the procedures included in the protocol.

        Exclusion Criteria:

          -  Intolerance/allergy to metformin or testosterone undecanoate.

          -  Previous diagnosis of diabetes mellitus (HbA1c&gt; 6.5% or fasting glucose&gt; 126 mg/dl or
             glucose&gt; 200 mg/dl after an oral glucose tolerance test)

          -  Treatment with oral hypoglycemic agents, insulin or GLP-1 analogs.

          -  Poor kidney function: serum creatinine&gt; 2.0 mg / dl.

          -  Previous history of prostate cancer or breast cancer.

          -  Active cancer of any kind.

          -  History of liver tumor or acute or chronic liver disease with impaired liver function:
             total bilirubin&gt; 2.0 mg / dl or GOT levels three times the upper limit of normal.

          -  Central hypogonadism of organic cause

          -  Use in the past 12 months of any drug that affects the pituitary-gonadal axis.

          -  Use of oral testosterone, oral or transdermal within 2 weeks prior to study entry, or
             any testosterone ester in the last 6 weeks or testosterone undecanoate injection in
             the 6 months prior to study entry.

          -  Uncontrolled hypertension (SBP&gt; 160 mmHg or DBP&gt; 100 mmHg) despite adequate
             antihypertensive therapy.

          -  HIV infection or known active infection with HBV or HCV.

          -  Thrombotic or embolic disease.

          -  Heart disease, kidney or liver disease.

          -  Epilepsy or migraine not adequately controlled with treatment.

          -  Hematocrit&gt; 50% in the screening.

          -  PSA&gt; 4 ng / ml.

          -  Severe benign prostatic hypertrophy with an IPSS scale score over 19.

          -  Evidence of drug or alcohol abuse (&gt; 50 g alcohol / day)

          -  Hematological diseases that produce increased risk of bleeding after intramuscular
             injection.

          -  Serious underlying disease that might affect the patient's ability to participate in
             the study (eg ongoing infection, gastric ulcers, active autoimmune disease).

          -  Reduced life expectancy (&lt;12 months) by the presence of comorbidities or advanced
             terminals.

          -  Participation in another clinical trial within 30 days before study entry.

          -  Previous diagnosis of hemochromatosis

          -  Treatment with phosphodiesterase-5 inhibitors: sildenafil, tadalafil or vardenafil
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Carlos Fernandez-Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Victoria. Malaga</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Uiversitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2015</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypogonadism</keyword>
  <keyword>Obesity</keyword>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Metformin</keyword>
  <keyword>Weight Loss</keyword>
  <keyword>Insulin Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

